Treatment with peginterferon versus interferon in Chinese patients with chronic hepatitis C

Song, Zhao; Liu, Enqi; Wei, Kai; Wang, Y.; Li, Y.; Huang, Binke; Chen, Y.; Yang, Penghui

doi:10.1007/s10096-010-1051-7

Cited by 5 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31,32 Pegylated interferon has been shown to be more effective than plain interferon in treating patients with HCV infection for both genotype1 and non 1. 33 But in this study, since treatment response was available only in a small number of patients, no difference was noted.…”

Section: Discussionmentioning

confidence: 88%

Clinicopathological features and genotype distribution in patients with hepatitis C virus chronic liver disease

Abraham

Ramakrishna

Balekuduru

et al. 2009

Indian J Gastroenterol

View full text Add to dashboard Cite

This study confirms the preponderance of genotype 3 in Indian patients with HCV related chronic liver disease. Severe steatosis was seen only in genotype 3 and Mallory hyaline was very common in genotype 1. The small numbers of patients in non genotype 3 could be a reason for the apparent lack of histological differences between different HCV genotypes. Severe fibrosis seen in older age groups confirms that HCV infection is progressive and major acceleration of the disease process occurs after 40 years of age.

show abstract

Section: Discussionmentioning

confidence: 88%

Clinicopathological features and genotype distribution in patients with hepatitis C virus chronic liver disease

Abraham

Ramakrishna

Balekuduru

et al. 2009

Indian J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Various genotypes of HCV have showed different treatment effects. Patients with GT 2 and 3 can achieve relative high SVR of 70–80%, yet patients with GT 1 and 4 showed bad effect with the low SVR of 40–50% [ 259 – 262 ]. This may be ascribed to the different pathogenicity and replication ability of HCV with different GTs and the host cell factor [ 263 , 264 ].…”

Section: Resultsmentioning

confidence: 99%

Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution

Zhang

Chen

2017

Virol J

View full text Add to dashboard Cite

Due to the low fidelity of the RNA-dependent RNA polymerase, Hepatitis C virus (HCV) mutates quite frequently. There are seven genetically divergent genotypes (GTs) distributed in the world, each of which contains several closely related subtypes. The peer-reviewed literatures reporting the prevalence rate of HCV GTs in Chinese hospitalized patients were identified by systematic searching of three electronic databases, and the prevalence rates were pooled through 137 qualified studies. The significant difference between HCV GT and HCV viral load and severity of hepatitis were analyzed under Chi-squared or Fisher’s exact test. Data from epidemiological studies on hospitalized patients demonstrated that HCV GTs 1–6 have been found in China, of which 1b (62.78%(95% CI: 59.54–66.02%)) and 2a (17.39% (95% CI: 15.67–19.11%)) are the two predominant subtypes. HCV GTs and subtypes exhibits significant regional divergence. In North, Northwest, Northeast, East (except Jiangxi province) and Central China (except Hunan province), HCV-1b, 2a remain the two predominant subtypes; South China shows the most abundant genetic diversity that 14 subtypes were found, and HCV-3 in the Southwest China remains higher prevalent subtype than the other regions. In addition, co-infection in Liaoning province of Northeast China is the most diverse with 10 co-infection types, and Tibet has the highest rate of co-infection. The associations between HCV GTs and patients group, severity of illness and antiviral treatment efficacy were also discussed in this review.

show abstract

“…Therefore, to reduce the effect of possible confounding factors, and we applied propensity-score matching to the two groups. This use of propensity score matching to eliminate confounding factors is a unique strength of the present study as it was not performed in previous retrospective studies [20-22]. …”

Section: Discussionmentioning

confidence: 99%

Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population

Jin

Lee

et al. 2013

BMC Gastroenterol

View full text Add to dashboard Cite

BackgroundTwo recent Italian studies suggested that Pegylated-interferon (PEG-IFN) alfa-2a achieves a higher sustained virological response (SVR) rate than PEG-IFN alfa-2b. We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV).MethodsThis retrospective, multi-center trial was conducted on 661 treatment-naïve chronic HCV patients. Patients received PEG-IFN alfa-2a (180 μg/week; n=402) or PEG-IFN alfa-2b (1.5 μg/kg/week; n=259) with ribavirin (800–1200 mg/day) for 24 or 48 weeks according to HCV genotypes.ResultsEarly virologic response and sustained virologic response (SVR) rates were not significantly different between two PEG-IFN groups both in patients with HCV genotype 1 (all P-values>0.05) and 2/3 (all P-values>0.05). SVR rates were not different between two groups in each categorized baseline characteristics: age (years) (≤50 and >50), HCV viral load (IU/mL) (≤7×105 and >7×105), and hepatic fibrosis (F0-2 and F3-4) (all P-values >0.05). In additional analysis for 480 patients who sufficiently complied with treatment doses and duration (80/80/80 rule) and propensity-score matched analysis, SVR rates were not different between two groups both in patients with HCV genotype 1 and 2/3 (all P-values >0.05). Adverse event rates were similar between two groups.ConclusionsUnlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis.

show abstract

Treatment with peginterferon versus interferon in Chinese patients with chronic hepatitis C

Cited by 5 publications

References 18 publications

Clinicopathological features and genotype distribution in patients with hepatitis C virus chronic liver disease

Clinicopathological features and genotype distribution in patients with hepatitis C virus chronic liver disease

Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution

Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population

Contact Info

Product

Resources

About